[go: up one dir, main page]

AU2001229252A1 - Method for the treatment of renal dysfunction with spla2 inhibitors - Google Patents

Method for the treatment of renal dysfunction with spla2 inhibitors

Info

Publication number
AU2001229252A1
AU2001229252A1 AU2001229252A AU2925201A AU2001229252A1 AU 2001229252 A1 AU2001229252 A1 AU 2001229252A1 AU 2001229252 A AU2001229252 A AU 2001229252A AU 2925201 A AU2925201 A AU 2925201A AU 2001229252 A1 AU2001229252 A1 AU 2001229252A1
Authority
AU
Australia
Prior art keywords
treatment
renal dysfunction
spla2 inhibitors
spla2
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001229252A
Other languages
English (en)
Inventor
William Louis Macias
Vincent Phillip Meador
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001229252A1 publication Critical patent/AU2001229252A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AU2001229252A 2000-03-09 2001-01-16 Method for the treatment of renal dysfunction with spla2 inhibitors Abandoned AU2001229252A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18803900P 2000-03-09 2000-03-09
US60188039 2000-03-09
PCT/US2001/000007 WO2001066110A2 (fr) 2000-03-09 2001-01-16 PROCEDE DE TRAITEMENT DU DYSFONCTIONNEMENT RENAL AU MOYEN D'INHIBITEURS DE sPLA¿2?

Publications (1)

Publication Number Publication Date
AU2001229252A1 true AU2001229252A1 (en) 2001-09-17

Family

ID=22691545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001229252A Abandoned AU2001229252A1 (en) 2000-03-09 2001-01-16 Method for the treatment of renal dysfunction with spla2 inhibitors

Country Status (4)

Country Link
EP (1) EP1265607A2 (fr)
JP (1) JP2003525901A (fr)
AU (1) AU2001229252A1 (fr)
WO (1) WO2001066110A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
RU2128169C1 (ru) * 1994-04-01 1999-03-27 Эли Лилли Энд Компани Iн-индол-3-глиоксиламиды, ингибирующие spla2-медиируемое выделение жирных кислот, фармацевтическая композиция
NZ298145A (en) * 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
CA2203912A1 (fr) * 1995-09-01 1997-03-13 Dennis Michael Zimmerman Antagonistes du recepteur du neuropeptide y indolyle
KR20010034552A (ko) * 1998-03-03 2001-04-25 요시히코 시오노 포스포리파제 저해제인 소듐[[3-(2-아미노-1,2-디옥소에틸)-2-에틸-1-(페닐메틸)-1ｈ-인돌-4-일]옥시]아세테이트를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
EP1265607A2 (fr) 2002-12-18
JP2003525901A (ja) 2003-09-02
WO2001066110A2 (fr) 2001-09-13
WO2001066110A3 (fr) 2002-04-25

Similar Documents

Publication Publication Date Title
AU2001269939A1 (en) Methods for eliminating the formation of biofilm
AU2001234088A1 (en) TNF-alpha inhibitors
HUP0303803A3 (en) Enzymatic method for the enantioselective reduction of keto compounds
AU2001258771A1 (en) -secretase inhibitors
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2001239833A1 (en) Phosphate removal from water
AU2003258855A1 (en) Method for the reduction of acrylamide formation
AU2001260674A1 (en) TNF-alpha production inhibitors
AU5981101A (en) Method for the prevention of apoptosis
AU2002326949A1 (en) Method for the inhibition of methanogenesis
AUPR618401A0 (en) Method for determining soil salinity
AU2001236052A1 (en) Urease inhibitors
AU2001286983A1 (en) Method of treatment
AU2001244562A1 (en) Neovascularization inhibitors
AU2001230207A1 (en) Method for the production of 1-amino-3-aryl-uracils
AU2001232245A1 (en) Tnf- alpha inhibitors
AU2002224550A1 (en) Corrosion inhibitors
GB0030284D0 (en) Enzyme inhibitors
AU2001252884A1 (en) Method of dopamine inhibition using l-threo-methylphenidate
IL155769A0 (en) Method for the treatment of inflammation
AU2001278698A1 (en) Pipe joining method
AU2001236440A1 (en) Method for the treatment of inflammation with spla2 inhibitors
AU2000275972A1 (en) Pde iii inhibitors for treating sexual dysfunction
AU2001229252A1 (en) Method for the treatment of renal dysfunction with spla2 inhibitors
AU2001243248A1 (en) Method for the prevention or reduction of vascular access dysfunction